Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Aldrich

Showing results (21-30 of 87) with videos related to

Pageof 9
Sort By:
Biopolymers|March 3, 2004
Synthesis of novel basic head-to-side-chain cyclic dynorphin A analogs: strategies and side reactionsBalvinder S Vig, Thomas F Murray, Jane V Aldrich
The Journal of Peptide Research : Official Journal of the American Peptide Society|March 25, 2005
Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonistM A Bennett, T F Murray, J V Aldrich
Journal of Medicinal Chemistry|October 23, 2015
Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist ZyklophinAnand A Joshi, Thomas F Murray, Jane V Aldrich
Proceedings of the National Academy of Sciences of the United States of America|October 21, 2009
Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of actionJane V Aldrich, Kshitij A Patkar, Jay P McLaughlin
Bioorganic & Medicinal Chemistry|December 24, 2017
Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(allyl)Wei-Jie Fang, Thomas F Murray, Jane V Aldrich
Biopolymers|June 19, 2010
Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 1: effects of cleavage conditions and N-terminal functionalityWei-Jie Fang, Marco A Bennett, Jane V Aldrich
Journal of Medicinal Chemistry|April 4, 2003
A novel N-terminal cyclic dynorphin A analogue cyclo(N,5)[Trp(3),Trp(4),Glu(5)] dynorphin A-(1-11)NH(2) that lacks the basic N-terminusBalvinder S Vig, Thomas F Murray, Jane V Aldrich
Chirality|March 29, 2001
Dynorphin A analogs containing a conformationally constrained phenylalanine derivative in position 4: reversal of preferred stereochemistry for opioid receptor affinity and discrimination of kappa vs. delta receptorsJ V Aldrich, Q I Zheng, T F Murray
Journal of Medicinal Chemistry|October 8, 2009
The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analoguesKshitij A Patkar, Thomas F Murray, Jane V Aldrich
Cancer Biology & Therapy|September 13, 2013
Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatmentArchana Mukhopadhyay, Kayann Tabanor, Rathnam Chaguturu, et al.
Pageof 9

Showing results (21-30 of 87) with videos related to

Sort By:
Pageof 9
Biopolymers|March 3, 2004
Synthesis of novel basic head-to-side-chain cyclic dynorphin A analogs: strategies and side reactionsBalvinder S Vig, Thomas F Murray, Jane V Aldrich
The Journal of Peptide Research : Official Journal of the American Peptide Society|March 25, 2005
Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonistM A Bennett, T F Murray, J V Aldrich
Journal of Medicinal Chemistry|October 23, 2015
Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist ZyklophinAnand A Joshi, Thomas F Murray, Jane V Aldrich
Proceedings of the National Academy of Sciences of the United States of America|October 21, 2009
Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of actionJane V Aldrich, Kshitij A Patkar, Jay P McLaughlin
Bioorganic & Medicinal Chemistry|December 24, 2017
Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(allyl)Wei-Jie Fang, Thomas F Murray, Jane V Aldrich
Biopolymers|June 19, 2010
Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 1: effects of cleavage conditions and N-terminal functionalityWei-Jie Fang, Marco A Bennett, Jane V Aldrich
Journal of Medicinal Chemistry|April 4, 2003
A novel N-terminal cyclic dynorphin A analogue cyclo(N,5)[Trp(3),Trp(4),Glu(5)] dynorphin A-(1-11)NH(2) that lacks the basic N-terminusBalvinder S Vig, Thomas F Murray, Jane V Aldrich
Chirality|March 29, 2001
Dynorphin A analogs containing a conformationally constrained phenylalanine derivative in position 4: reversal of preferred stereochemistry for opioid receptor affinity and discrimination of kappa vs. delta receptorsJ V Aldrich, Q I Zheng, T F Murray
Journal of Medicinal Chemistry|October 8, 2009
The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analoguesKshitij A Patkar, Thomas F Murray, Jane V Aldrich
Cancer Biology & Therapy|September 13, 2013
Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatmentArchana Mukhopadhyay, Kayann Tabanor, Rathnam Chaguturu, et al.
Pageof 9